Literature DB >> 21925791

The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line.

Igor Tsaur1, Jasmina Makarević, Lukasz Hudak, Eva Juengel, Martin Kurosch, Christoph Wiesner, Georg Bartsch, Sebastian Harder, Axel Haferkamp, Roman A Blaheta.   

Abstract

The growth potential of PC3 prostate cancer cells, sensible (PC3(par)) or resistant (PC3(res)) to the mTOR inhibitor everolimus (RAD001) was investigated. Cell growth and proliferation of PC3(res) was similar to that of PC3(par), and late apoptosis increased in PC3(par) but decreased in PC3(res) following treatment with low dosed everolimus. PC3(res) accumulated in the G2/M-phase, accompanied by cdk1, cdk2 and cyclin B elevation. Knocking down cdk1 or cyclin B distinctly blocked the growth activity of PC3(res). One reason for everolimus resistance may be up-regulation of the cdk1-cyclin B complex in prostate cancer cells, leading to enhanced progression towards G2/M.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21925791     DOI： 10.1016/j.canlet.2011.08.026

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  24 in total

1.  Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice.

Authors:  Ammar Kurdi; Mireille De Doncker; Arthur Leloup; Hugo Neels; Jean-Pierre Timmermans; Katrien Lemmens; Sandra Apers; Guido R Y De Meyer; Wim Martinet
Journal:  Br J Pharmacol       Date:  2016-10-23       Impact factor: 8.739

2.  Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.

Authors:  Eva Juengel; Jasmina Makarević; Michael Reiter; Jens Mani; Igor Tsaur; Georg Bartsch; Axel Haferkamp; Roman A Blaheta
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

Review 3.  Ceramide-orchestrated signalling in cancer cells.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Nat Rev Cancer       Date:  2012-12-13       Impact factor: 60.716

4.  A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signaling in human prostate cancer cells.

Authors:  Karishma S Amin; Shankar Jagadeesh; Gakul Baishya; Paruchuri G Rao; Nabin C Barua; Samir Bhattacharya; Partha P Banerjee
Journal:  Mol Cancer Ther       Date:  2013-11-20       Impact factor: 6.261

5.  Endometriosis Cell Proliferation Induced by Bone Marrow Mesenchymal Stem Cells.

Authors:  Peng Chen; Ramanaiah Mamillapalli; Shutaro Habata; Hugh S Taylor
Journal:  Reprod Sci       Date:  2020-08-18       Impact factor: 3.060

Review 6.  Potential therapeutic effects of mTOR inhibition in atherosclerosis.

Authors:  Ammar Kurdi; Guido R Y De Meyer; Wim Martinet
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

7.  Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway.

Authors:  Guangjie Ji; Shiming He; Cong Huang; Yanqing Gong; Xuesong Li; Liqun Zhou
Journal:  Int J Biol Sci       Date:  2021-04-12       Impact factor: 6.580

8.  Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells.

Authors:  I Tsaur; J Makarević; E Juengel; M Gasser; A-M Waaga-Gasser; M Kurosch; M Reiter; S Wedel; G Bartsch; A Haferkamp; C Wiesner; R A Blaheta
Journal:  Br J Cancer       Date:  2012-07-10       Impact factor: 7.640

9.  Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.

Authors:  Eva Juengel; Dana Kim; Jasmina Makarević; Michael Reiter; Igor Tsaur; Georg Bartsch; Axel Haferkamp; Roman A Blaheta
Journal:  J Cell Mol Med       Date:  2014-12-02       Impact factor: 5.310

10.  Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.

Authors:  Igor Tsaur; Lukasz Hudak; Jasmina Makarević; Eva Juengel; Jens Mani; Hendrik Borgmann; Kilian M Gust; David Schilling; Georg Bartsch; Karen Nelson; Axel Haferkamp; Roman A Blaheta
Journal:  J Cell Mol Med       Date:  2015-03-26       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.